Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improving clinical trial outcomes in amyotrophic lateral sclerosis
Matthew C. Kiernan, Steve Vucic, Kevin Talbot, et al.
Nature Reviews Neurology (2020) Vol. 17, Iss. 2, pp. 104-118
Open Access | Times Cited: 225

Showing 1-25 of 225 citing articles:

Amyotrophic lateral sclerosis
Eva L. Feldman, Stephen A. Goutman, Susanne Petri, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1363-1380
Open Access | Times Cited: 526
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis
Stephen A. Goutman, Orla Hardiman, Ammar Al‐Chalabi, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 5, pp. 480-493
Open Access | Times Cited: 273
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Richard J. Mead, Ning Shan, H. Joseph Reiser, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 185-212
Open Access | Times Cited: 250
Lysosomal dysfunction in neurodegeneration: emerging concepts and methods
Vinod Udayar, Yu Chen, Ellen Sidransky, et al.
Trends in Neurosciences (2022) Vol. 45, Iss. 3, pp. 184-199
Open Access | Times Cited: 131
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers
Björn F. Vahsen, Elizabeth Gray, Alexander G. Thompson, et al.
Nature Reviews Neurology (2021) Vol. 17, Iss. 6, pp. 333-348
Open Access | Times Cited: 117
Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee
Steve Vucic, Kai-Hsiang Chen, Matthew C. Kiernan, et al.
Clinical Neurophysiology (2023) Vol. 150, pp. 131-175
Open Access | Times Cited: 110
Skeletal muscle in amyotrophic lateral sclerosis
Jeremy M. Shefner, Antonio Musarò, Shyuan T. Ngo, et al.
Brain (2023) Vol. 146, Iss. 11, pp. 4425-4436
Open Access | Times Cited: 44
Restoring arm function with a soft robotic wearable for individuals with amyotrophic lateral sclerosis
Tommaso Proietti, Ciaran O’Neill, Lucas Gerez, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 681
Closed Access | Times Cited: 43
Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives
Ramyar Rahimi Darehbagh, Seyedeh Asrin Seyedoshohadaei, Rojin Ramezani, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 20
Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation
Elisa Giacomelli, Björn F. Vahsen, Elizabeth L. Calder, et al.
Cell stem cell (2022) Vol. 29, Iss. 1, pp. 11-35
Open Access | Times Cited: 66
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents
Stephen A. Johnson, Ton Fang, Fabiola De Marchi, et al.
Drugs (2022) Vol. 82, Iss. 13, pp. 1367-1388
Closed Access | Times Cited: 62
Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives
Stefano Raffaele, Marta Boccazzi, Marta Fumagalli
Cells (2021) Vol. 10, Iss. 3, pp. 565-565
Open Access | Times Cited: 61
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
Kim A. Staats, David Borchelt, Malú G. Tansey, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 51
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis
Ryosuke Oki, Yuishin Izumi, Koji Fujita, et al.
JAMA Neurology (2022) Vol. 79, Iss. 6, pp. 575-575
Open Access | Times Cited: 44
Nanoparticle-Based Drug Delivery Systems: An Inspiring Therapeutic Strategy for Neurodegenerative Diseases
Linyan Duan, Xingfan Li, Rong Ji, et al.
Polymers (2023) Vol. 15, Iss. 9, pp. 2196-2196
Open Access | Times Cited: 40
UNC13Ain amyotrophic lateral sclerosis: from genetic association to therapeutic target
Sean W. Willemse, Peter Harley, Ruben P.A. van Eijk, et al.
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 94, Iss. 8, pp. 649-656
Open Access | Times Cited: 35
Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology
Oliver J. Ziff, Jacob Neeves, Jamie S. Mitchell, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 34
Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures
Stephen A. Johnson, Marta Karas, Katherine M. Burke, et al.
npj Digital Medicine (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 31
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension
Steve Vucic, Parvathi Menon, William Huynh, et al.
EClinicalMedicine (2023) Vol. 60, pp. 102036-102036
Open Access | Times Cited: 26
A multi-laboratory preclinical trial in rodents to assess treatment candidates for acute ischemic stroke
Patrick D. Lyden, Márcio A. Diniz, Francesca Bosetti, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 714
Closed Access | Times Cited: 26
At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis
Anoopum S. Gupta, Siddharth Patel, Alan Premasiri, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 24
Ultrasound–enhanced brain delivery of edaravone provides additive amelioration on disease progression in an ALS mouse model
Yuanyuan Shen, Ji Zhang, Yiluo Xu, et al.
Brain stimulation (2023) Vol. 16, Iss. 2, pp. 628-641
Closed Access | Times Cited: 22
Opinion: more mouse models and more translation needed for ALS
Elizabeth Fisher, Linda Greensmith, Andrea Malaspina, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 22
TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS
Jing Yan, Yumeng Wang, Andrea Hellwig, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101413-101413
Open Access | Times Cited: 8
Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases
Ching‐Pang Chang, Kuo-Chen Wu, Chien‐Yu Lin, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top